Our Saturday green news brings you the latest on health, parenting and cool baby and kid products:
- The best whooping cough prevention: Based on a new study recently published in the journal Pediatrics, the best best whooping cough prevention for a baby is to ensure the baby has been vaccinated. Although the vaccine can’t guarantee that a baby who contracts the disease won’t die, it drops the risk by 72%. According to the study, majority of the babies who did die were under 6 weeks of age, which is the earliest age when the DTaP (the pertussis, or whooping cough, vaccine) can be given. Among more than 45,000 children under age 1 who had pertussis between 1991 and 2008, about a half percent of them (258 infants) died, every one of them under 8 months old. But if they had received at least their first dose of the DTaP vaccine, their odds were 72% lower of dying, 31% lower of being hospitalized and 20% lower of developing pneumonia. Plus another recent study confirmed, that immunity to pertussis virus in older children fades rapidly after their booster doses. This fact most likely contributes to the increasing rates of the disease. Therefore the Global Pertussis Initiative recommends that the best way to protect babies from pertussis until their first round of shots is to vaccinate mothers toward the end of their pregnancy. They also recommend to keep vaccinating teens, at least those likely to be around any newborns, who are very vulnerable to the disease.
- FDA warns about new drugs for type 2 diabetes: The FDA (U.S. Food and Drug Administration) recently warned that a widely used newer class of type 2 diabetes drugs may cause dangerously high levels of blood acids that could require hospitalization. These drugs include AstraZeneca’s Farxiga (dapagliflozin), J&J’s Invokana (canagliflozin) and Jardiance (embagliflozin) from Lilly and Boehringer.